2025 FDA Approvals: Innovation Holds Steady in First Year Under New Leadership
Under the FDA’s new leadership, 2025 saw the approval of 46 new molecular entities and 10 new biologics, matching the pace of recent years. The agency’s review process remained on schedule, suggesting that the transition in senior management has not disrupted innovation pipelines. Analysts note that the steady approval volume underscores continued investment in drug development across small‑molecule and biologic platforms. The data signal that regulatory stability persists despite leadership changes.
Independent Low-Cost Vaccines Keep Pfizer Out of Markets
ANS: I don’t take a dime from Pfizer or any other big pharma company. If and when you decide to visit a library instead of relying on conspiracy sites, you’ll find we develop low cost, patent free vaccines that bypass...
Albendazole’s Impact on Helminths in Yunnan Kids
Researchers evaluated a school‑based albendazole deworming program among 3,200 children aged 5‑12 in Yunnan province. Baseline surveys showed a 42% helminth infection rate, which fell to 13% after a single annual dose. The intervention also correlated with modest gains in...
JPM Acts as Audit, Reveals Biotech Translation Friction
JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
OpenAI Brings ChatGPT to Hospitals on the Heels of Launching Consumer Health Tool
OpenAI unveiled ChatGPT for Healthcare, extending its popular conversational AI into hospitals and health systems. The offering follows the recent launch of a consumer‑focused health tool, signaling a broader push into clinical environments. OpenAI says the service will integrate with...
Expert Consensus on Validating Internal Jugular Ultrasound Tool
A panel of leading emergency physicians, intensivists, and radiologists released an expert consensus outlining a structured validation pathway for internal jugular vein ultrasound (IJU) tools. The framework delineates three validation phases—technical performance, operator reproducibility, and clinical outcome impact—backed by specific...
Evaluating Acupuncture for Cancer Treatment Fatigue: A Review
A recent systematic review examined acupuncture as a therapeutic option for cancer‑related fatigue, analyzing data from 18 randomized controlled trials involving over 2,000 patients. The analysis found that acupuncture produced modest but statistically significant reductions in fatigue severity compared with...
New Framework Enhances Climate Health Vulnerability Analysis
A multidisciplinary research team has unveiled a new analytical framework that fuses high‑resolution climate data with population health metrics to assess climate‑related health vulnerability. The platform leverages machine‑learning‑driven spatial modeling, incorporating temperature, air‑quality, and socioeconomic indicators to predict disease risk...
Investors Now Require Clean Data and Clear Milestones
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...
Microbial Communities and Tight Junctions in Cattle’s Gut
A new study links specific microbial communities to the integrity of tight junction proteins in the bovine gut, showing that a higher abundance of *Ruminococcus* and *Lactobacillus* correlates with stronger barrier function. Metagenomic sequencing and intestinal tissue analysis revealed a...
Deformable Adjuvants Can Enhance Immune Activation in New Vaccine Design
Researchers at the Chinese Academy of Sciences have engineered aluminum‑stabilized Pickering emulsions (ASPE) that act as deformable adjuvants, providing mechanical cues to dendritic cells. By adjusting nanoparticle crystallinity, the interfacial stiffness can be tuned to activate the mechanosensitive PIEZO1 channel,...
Aberrant Calcium Signaling and Neuronal Activity in the L271H CACNA1D (Cav1.3) iPSC Model of Neurodevelopmental Disease
Researchers created the first patient‑derived iPSC model carrying the de novo L271H CACNA1D (Ca_v1.3) variant linked to neurodevelopmental disease. The study shows that Ca_v1.3 is the dominant L‑type calcium channel in neural progenitor cells, where the mutation drives heightened spontaneous calcium...
TIGIT Disruption Boosts Low-Avidity T Cell Tumor Attack
Researchers have demonstrated that genetic disruption of the inhibitory receptor TIGIT markedly amplifies the anti‑tumor activity of low‑avidity T cells. In mouse models, TIGIT‑deficient T cells infiltrated tumors more efficiently and induced significant tumor regression, especially when paired with existing...
WRKY Gene Family’s Role in Cucurbita Moschata Resistance
Researchers have identified specific WRKY transcription factors that enhance disease resistance in Cucurbita moschata, commonly known as winter squash. Using genome‑wide association studies and CRISPR‑mediated knock‑outs, the team pinpointed WRKY45 and WRKY70 as key regulators against Phytophthora blight. Field trials...
Noncanonical TRPM4 Controls Intestinal Fluid Balance
Researchers have identified a noncanonical isoform of the TRPM4 ion channel that directly regulates intestinal fluid secretion and absorption. Using mouse models and human intestinal organoids, the study showed that loss of this isoform leads to dysregulated electrolyte transport and...
METTL3 Loss Drives Glioma via Macrophage Lipids
Researchers have discovered that loss of the RNA methyltransferase METTL3 accelerates glioma progression by reprogramming macrophage lipid metabolism. The study shows METTL3‑deficient tumor cells induce lipid accumulation in tumor‑associated macrophages, creating an immunosuppressive microenvironment that fuels tumor growth. Mechanistic analysis...
Designing Liver Simulants with Hyperelastic Micromechanics
On January 9, 2026 Bioengineer.org published a suite of research highlights spanning nanomedicine, parasitology, medical imaging, climate‑health analytics, and plant genetics. The pieces report that chlorella‑based nanogels markedly suppress lung injury inflammation, albendazole effectively reduces helminth burdens in Yunnan children, and an...
Merck in Talks to Acquire Revolution Medicines, Deal Uncertain
Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology...
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx
Sanofi Calls Rejection of Potential MS Blockbuster 'Unexpected'
Sanofi announced that the FDA rejected its experimental multiple‑sclerosis therapy, labeling the decision unexpected. The agency raised substantive questions late in the review process, leaving insufficient time for Sanofi to amend its submission. The setback threatens the anticipated launch of...
Multi-Omic Atlas Shows Women’s Stronger Immunity, Age‑Related Decline
We're learning more about our immune system from a new, comprehensive, multi-omic atlas in @ScienceMagazine today, such as the stronger immune system in women and the age-related features of immunosenescence https://t.co/4B85BwohBb https://t.co/DHNIUKcQmE
Illumina Hires Eric Green as Chief Medical Officer
Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute and a pioneering geneticist, as its new chief medical officer. Green will lead the company’s clinical strategy, regulatory affairs, and diagnostic product development. The...
How Light Reflects on Leaves May Help Researchers Identify Dying Forests
Researchers at the University of Notre Dame have demonstrated that leaf spectral reflectance measured from airborne or satellite sensors can predict the expression of key stress‑related genes. By sampling sugar maple and red maple leaves in Wisconsin and Michigan, they...
AlphaFold Sparks Surge in Genome-Wide Drug Discovery
In the post-AlphaFold era, drug discovery is on a tear —Genome-wide virtual screening @ScienceMagazine https://t.co/GPyjSK6PcM —Transforming the industry in many ways @TheEconomist https://t.co/ppAMkbFqMp
Stem Cell-Derived Neurons Navigate to Form Connections in the Injured Brain
Researchers at Sanford Burnham Prebys and Duke‑NUS have demonstrated that human embryonic stem cell‑derived cortical neurons can be grafted directly into the lesion cavity of mice after ischemic stroke, survive, mature into NeuN‑positive neurons, and re‑establish long‑range connections. By tracing...
In Search of Mechanisms to Explain the Sex Difference in Alzheimer's Disease Outcomes
Recent open‑access research confirms that women experience more severe Alzheimer’s pathology than men, with female 5xFAD mice developing larger, less compact amyloid‑β plaques. Transcriptomic analysis revealed that female microglia up‑regulate glycolytic metabolism, antigen‑presentation pathways, and a distinct type‑I interferon signature,...
Science Spotlight: Thwarting Melanoma Immune Evasion
Researchers have uncovered new molecular pathways that melanoma cells use to dodge immune surveillance, focusing on PD‑L1 up‑regulation and downstream signaling. A high‑throughput CRISPR‑Cas9 screen pinpointed several previously unknown evasion genes, enabling a targeted combination‑therapy approach. Early‑phase trials combining checkpoint...
FDA Staff Cuts Mostly Didn't Impact New Drug Review Timelines, Analysis Finds
Despite thousands of staff cuts, retirements, and leadership departures at the FDA in 2025, the agency’s drug reviewers largely maintained their review schedules. An internal analysis shows that median approval times for new molecular entities shifted by less than one...
Healing Brain Cells and Tackling Neurodegenerative Diseases with Nanoflowers
Researchers at Texas A&M have shown that metallic “nanoflower” nanoparticles can protect and repair brain cells by improving mitochondrial health. In cell cultures, the nanoflowers sharply lowered reactive oxygen species and enhanced mitochondrial integrity within a day, and in C....
Lilly Tests Zepbound to Drive Taltz Sales
$LLY runs a psoriatic arthritis marketing study of Zepbound hoping to boost sales of Taltz. @elaineywchen sees right through it. Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms https://t.co/pcmEhIZgWY
New Lilly Data Suggest Zepbound Boosted Effect of Autoimmune Drug
Eli Lilly’s Phase 3b trial shows its weight‑loss blockbuster Zepbound (tirzepatide) can amplify the efficacy of an existing autoimmune therapy in a targeted patient cohort. The combination yielded superior clinical endpoints compared with the autoimmune drug alone, suggesting a synergistic...
Rampart's Fall Highlights Struggles in Legacy Gene Therapy
Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...
Secretive Rampart Bioscience Closes After Pursuing Non-Viral Gene Therapy
Rampart Bioscience, a stealth biotech founded less than 15 months ago with a $125 million Series A, announced its closure after failing to advance its non‑viral gene‑therapy platform. The company had aimed to address delivery challenges that have limited viral vectors, but...
AI-Driven Tracking of Tumor Evolution Reshapes Cancer Therapy
The plan to revolutionize cancer treatment by tracking and responding to evolution of tumor, emergence of resistance, and multimodal AI https://t.co/9PhOrtkiBM @Cancer_Cell @ARPA_H
Cellular Reprogramming Paves Path to Anti‑Aging Organs
Anti-aging and organ rejuvenation strategies, a review https://t.co/ZycCqjZwKk @CellStemCell Figure summary of cellular reprogramming efforts https://t.co/YKgGKukuYb
MoonLake Revives FDA Push; Biotech Trio to Debut in Hong Kong
MoonLake Immunotherapeutics has re‑filed its FDA application for a novel therapy targeting a rare dermatological disorder, aiming to overcome earlier regulatory setbacks. The company highlighted new clinical data showing a 45% improvement in lesion clearance among trial participants. Simultaneously, three...
Treg Breakthroughs: Nobel‑winning Science Moves Toward Clinics
The science of regulatory T cells (Tregs) got the @NobelPrize last year. Now a first-rate review of where they are headed in the clinical arena https://t.co/4xjNAeG3MV https://t.co/MZCDyBc4jq
Rapid Sterility Test Considerations
Rapid sterility testing (RST) is reshaping pharmaceutical quality control by cutting release times to roughly six days and providing objective, non‑visual detection methods. Nelson Labs highlights its ATP bioluminescence platform, which requires product‑specific validation, expanded organism panels, and interference studies...
FDA Drug and Biologic Approvals List 2025: Sign-Offs Dip During Agency Upheaval
The FDA’s 2025 drug and biologic approval tally fell sharply amid a year of internal upheaval. Approvals dropped about 15% compared with 2024, reflecting slower review times as thousands of staff departed and senior leadership changed. The agency’s operational instability...
FDA's Prasad Paradox: Conflicting Strictness on Bespoke Therapies
Predictions for cell therapy and gene therapy in 2026. Most interesting is the "Prasad Paradox", meaning a general state of contradiction at the FDA biologics division around laxness and strictness, including misapplication of the concept of "bespoke" therapies.
HHS Loses Bid to Suspend Court Block on 340B Rebate Pilot
The U.S. Department of Health and Human Services (HHS) failed to overturn a federal court order that barred the launch of its 340B rebate pilot. A three‑judge panel of the U.S. Court of Appeals affirmed the lower‑court injunction, keeping the...
Cloning Error Deletes Lac Operator and T5 Promoter
Man, not my lucky day with cloning. A positive control plasmid had one of its lac operators and the -10 element of the T5 promoter removed during cloning. Gonna screen a few more. https://t.co/O09jf6Qf7F
Parabilis Secures $305M, CEO Signals IPO Plans
Mathai on quarterly conference calls? Parabilis Medicines raises $305 million as CEO warms to an IPO By @ADeAngelis_bio https://t.co/h6I9BXDuLS via @statnews
Tessera Trimming 90 Employees as Part of Pipeline Prioritization
A wave of workforce reductions swept the biotech sector in early 2024, with Tessera Therapeutics cutting 90 employees (about 35% of its staff) to prioritize its AATD and sickle‑cell programs after a $275 million Regeneron partnership. Similar cuts hit companies ranging...
Vanda Slides After FDA Again Rejects Hetlioz For Jet Lag
Vanda Pharmaceuticals’ sleep‑aid Hetlioz was again rejected by the FDA for a jet‑lag indication, despite the agency acknowledging positive efficacy in trials. The regulator objected to Vanda’s reliance on phase‑advance protocols, deeming them insufficiently representative of real‑world travel conditions. The...
Deregulating the Rapidly Evolving Digital Health Industry
The article examines how governments are loosening regulations to accommodate the fast‑moving digital health sector, especially AI‑driven diagnostics and telemedicine. Recent policy proposals aim to streamline FDA approvals, expand data‑sharing frameworks, and create sandboxes for experimental AI tools. OpenAI’s latest...
Charles River CEO Jim Foster to Retire; Samsung Bio Buys a GSK Factory
Charles River Laboratories announced that CEO James C. Foster will retire on May 5 after more than a decade at the helm, and the board has named longtime COO Dr. Laura Miller as his successor. The transition comes as the company seeks...
Top 10 Most Popular Drug Hunter Resources of 2025
Drug Hunter’s 2025 resource roundup highlights the ten most accessed tools that support daily drug‑discovery workflows. The suite includes practical PK calculators, bioisostere and covalent inhibitor cheat sheets, a searchable structure and patent database, and a series of 25 Flash...
Ocular Therapeutix's Durable Eye Therapy Faces Upcoming Test
This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://t.co/XTI2wySnbB
Dataset in Hg19 Forces Costly Remapping to Hg38
1/ Found the perfect ChIP-seq dataset on GEO. Then saw "hg19" in the methods. Now you need to remap everything to hg38 before you can integrate it with your data. And the authors didn't share their processing pipeline. https://t.co/3Ui4dyEnkb